Article

Mmvtelegraph.com on 2023-03-09 10:05

Eli Lilly’s therapy with solanezumab didn’t decelerate the illness

Eli Lilli on Wednesday said it would halt development of its Alzheimer's treatment candidate solanezumab after the antibody failed to slow the ...

Brigham City

Related news

FDA Authorizes Eli Lilly’s Covid Antibody Therapy For Emergency Use In Young Children Forbes
BVir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again barrons.com
Vír
Eli Lilly’s Profit Dented by Higher Costs wsj.com
US OKs new use for Eli Lilly’s COVID-19 treatment bangordailynews.com
Indianapolis
FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug Forbes
Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern The New York Times
Veterans Affairs
Eli Lilly’s New Compliance Chief on His Priorities6 min read wsj.com
Canada
Eli Lilly’s EFFIENT combination use patent found obvious jdsupra.com
California , United States , Switzerland
Eli Lilly’s sees strength in 2017, shares take off seattletimes.com
FHigh stakes: Eli Lilly’s hunt for an Alzheimer’s drug ft.com
South East Asia , China
Eli Lilly’s promising Alzheimer’s drug fails in clinical trials FOX 8 News Cleveland
Indiana , Indianapolis
BEli Lilly’s Earnings Raise Hopes for Pharmaceutical Stocks barrons.com
FFT Magazine: High stakes: Eli Lilly’s hunt for an Alzheimer’s drug ft.com
South East Asia , China
BEli Lilly’s Growth Is Set to Soar Under CEO David Ricks1 min read barrons.com
Denmark
ICramer reacts to Eli Lilly’s telehealth service for weight-loss drug invezz.com
FEli Lilly & Co: US regulator delays decision on Eli Lilly’s Alzheimer’s drug ft.com
FEli Lilly & Co: Eli Lilly’s Alzheimer’s drug wins backing of US advisory panel ft.com
What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDA Forbes
Indianapolis
FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment New York Post